-

21/12/2016
 
 |   |   |  |   |   |  
 

- ( ), . , , 100-1000 , (1-3).

, , .

,

- .

, -.

, " .

, -, .

 

 (Linum usitatissimum)

 

 |   |   |  | 

 

, -3 .

(Enterolactone), -0.00021% (3).

, -.

 

2010 -1122

1996-2001 2006. - 12-24

. ,

(4).

 

-2013 .

2999

-3370 . (5).

 

 2013,   .

1892 , 10 : 2 -, 2 -,

- (Biomarker Study) -5 . ,

HER2 ( ) -25 .

.

- -, , -,

- -25 , 50 " SDG .

, (6).

 

2010 (SDG) -45 .

SDG (50 " ) -12 Ki-67, , ,

. , , .

-36 Ki-67, (7).

 

-2010 , .

-2 –

(40 " ) -8 . ,

. , , (8).

 

2010 ,

. - .

, - .

-(9).

 

-2012 - , .

(10)  (MMP2, MMP9, MMP12).

 

2014, (Anastrozole)

-. . 24 , .

,

(11).

 

2012 , (Tamoxifen) -1 (IL-1), 

, . , , ,

. , -25 IL1-Ra, IL-1.

IL-1 - ,

IL-1 (12).

 

2010 (SDG) ,

- , .

-4 :

1. ,

2. SDG,

3. ,

4. SDG .

( , , ).

- , .

, ,

, SDG (13).

 

2013 , ,

HER-2.

-3 : , -10%

, -5 . -2 ,

5 - , (14).

 

 

-2001 , . 

-25 - ( -20% -) -30 ' . 

 PSA, , . 

, . 

-34 , , , PSA

, -(15).

 

 2008  /

. -161 ,  21 -,

-4 :

,

-1 -30 ,

-2 -

-3 , .

(PSA), (SHBG), , IGF,

C-reactive protein, LDL . , .

30 . - Ki-67,

.

, .

(16).

 

 2013  (Enterolactone) (Enterodiol),

- , NFkB, VEGF (- ) - Ki-67.

-161 , , -30 30 .

- - (IHC).

- .

- - Ki-67 , .

-VEGF, -NFkB (17).

 

 2002  , .

-135 – (AIN-76A)

5% . 20 30 .

.

, -100% -97% .

3.6 1.9 .

20 , 30

.

13% 16% , 5% 12% .

(18).

 

, .

-, , .

, " -, (19).

 

 2013, -, ,     .

– -10%, 4 .

.

1 -2 (COX 1&2), 2 (PGE2) mRNA .

, .

, , -2 -2 (20).

 

 2014  -.

.

, - .

-10% .

- ()

(E-cadherin).

- 40-60% .

, (miR-200).

(21).

 

, .

, , .

.

( 25-30 ) , .

, .

,

.

 

 

  1. Kuiper GG1, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA., Comparison of the lignin binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997 Mar;138(3):863-70.

  2. Mueller SO, Simon S, Chae K, Metzler M, Korach KS.,Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci. 2004 Jul;80(1):14-25.

  3. Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T, Kojima H. Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using Chinese hamster ovary cells. Biol Pharm Bull. 2009 Feb;32(2):195-202

  4. McCann SE, Thompson LU, Nie J, Dorn J, Trevisan M, Shields PG, Ambrosone CB, Edge SB, Li HF, Kasprzak C,Freudenheim JL. Dietary lignin intake in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2010 Jul;122(1):229-35.

  5. Lowcock EC, Cotterchio M, Boucher BA. Consumption of flaxseed, a rich source of lignans, is associated with reduced breast cancer risk. Cancer Causes Control. 2013 Apr;24(4):813-6.

  6. Flower G, Fritz H, Balneaves LG, Verma S, Skidmore B, Fernandes R, Kennedy D, Cooley K, Wong R, Sagar S, Fergusson D, Seely D. Flax and breast cancer: A systematic review. Integr Cancer Ther. 2013 Sep 8;13(3):181-192.

  7. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell KD, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh HW, Johnson KA Reduction in Ki-67 benign breast tissue of high-risk women with the lignin secoisolariciresinol diglycoside. Cancer Prev Res (Phila). 2010 Oct;3(10):1342-50.

  8. Truan JS, Chen JM, Thompson LU. Flaxseed oil reduces the growth of human breast tumors (MCF-7) at high levels of circulating estrogen. Mol Nutr Food Res. 2010 Oct; 54(10):1414-21.

  9. Richter DU, Abarzua S, Chrobak M, Scholz C, Kuhn C, Schulze S, Kupka MS, Friese K, Briese V, Piechulla B, Jeschke U. Effects of phytoestrogens extracts isolated from flax on estradiol production and ER/PR expression in MCF7 breast cancer cells. Anticancer Res. 2010 May;30(5):1695-9

  10. Mali AV, Wagh UV, Hegde MV, Chandorkar SS, Surve SV, Patole MV. In vitro anti-metastatic activity of enterolactone, a mammalian lignan derived from flax lignan, and down-regulation of matrix metalloproteinases in MCF-7 and MDA MB 231 cell lines. Indian J Cancer. 2012 Jan-Mar;49(1):181-7.

  11. McCann SE, Edge SB, Hicks DG, Thompson LU, Morrison CD, Fetterly G, Andrews C, Clark K, Wilton J, Kulkarni S. A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast cancer. Nutr Cancer. 2014;66(4):566-75.

  12. Abrahamsson A, Morad V, Saarinen NM, Dabrosin C. Estradiol, tamoxifen, and flaxseed alter IL-1B and IL-1Ra levels in normal human breast tissue in vivo. J Clin Endocrinol Metab. 2012 Nov;97(11):E2044-54.

  13. Saggar JK, Chen J, Corey P, Thompson LU. Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways. Mol Nutr Food Res. 2010 Mar;54(3):415-25.

  14. Mason JK, Fu MH, Chen J, Yu Z, Thompson LU. Dietary flaxseed-trastuzumab interactive effects on the growth of HER2- overexpressing human breast tumors (BT-474). Nutr Cancer. 2013;65(3):451-9.

  15. Demark-Wahnefried W1, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, Walther PJ, Gannon M,Vollmer RT. Pilot study of dietry fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001 Jul;58(1):47-52.
  16. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V,Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cacner proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87.

  17. Azrad M, Vollmer RT, Madden J, Dewhirst M, Polascik TJ, Snyder DC, Ruffin MT, Moul JW, Brenner DE, Demark-Wahnefried W. Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. J Med Food. 2013 Apr;16(4):357-60.

  18. Lin X, Gingrich JR, Bao W, Li J, Haroon ZA, Demark-Wahnefried W. Effects of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology. 2002 Nov;60(5):919-24.

  19. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Int J Gynecol Cancer. 2009 May;19(4):531-9.

  20. Eilati E, Bahr JM, Hales DB. Long term consumption of flaxseed enriched diet decreased ovarian cancer incidence and prostaglandin E2 in hens. Gynecol Oncol. 2013 Sep;130(3):620-8. doi: 10.1016/j.ygyno.2013.05.018.

  21. Hales KH, Speckman SC, Kurrey NK, Hales DB. Uncovering molecular events associated with the chemosuppressive effects of flaxseed: a microarray analysis of the laying hen model of ovarian cancer. BMC Genomics. 2014 Aug 24;15:709.